TY - JOUR
T1 - Smoldering multiple myeloma
T2 - the role of different scoring systems in identifying high-risk patients in real-life practice
AU - Cocito, Federica
AU - Mangiacavalli, Silvia
AU - Valeria Ferretti, Virginia
AU - Cartia, Claudio Salvatore
AU - Ganzetti, Maya
AU - Benveuti, Pietro
AU - Pompa, Alessandra
AU - Catalano, Martina
AU - Fugazza, Elena
AU - Landini, Benedetta
AU - Arcaini, Luca
AU - Corso, Alessandro
PY - 2019/1/1
Y1 - 2019/1/1
N2 - We explore the predictive role of 2014-updated International Myeloma Working Group (IMWG) diagnostic criteria and of some of currently available risk models for progression to symptomatic myeloma when applied in our unselected population of 75 smoldering multiple myeloma (SMM) patients observed between 2000 and 2015. Risk scores including routinely used clinical parameters such as bone marrow plasmacell infiltration rate, immunoparesis, serum monoclonal component (sMC) value, and altered free light chain ratio (FLCr), were clinically useful to identify SMM patients at higher risk of progression. Time to myeloma progression in our ultra-high risk SMM according to IMWG diagnostic update criteria was very short (12.4 months). Our analysis identified as independent reliable predictors of progression altered FLCr as well as increasing plasma cell infiltration which are part of most commonly applied risk models. Waiting for new scoring systems, bone marrow evaluation and complete laboratory screening are still milestones for SMM management.
AB - We explore the predictive role of 2014-updated International Myeloma Working Group (IMWG) diagnostic criteria and of some of currently available risk models for progression to symptomatic myeloma when applied in our unselected population of 75 smoldering multiple myeloma (SMM) patients observed between 2000 and 2015. Risk scores including routinely used clinical parameters such as bone marrow plasmacell infiltration rate, immunoparesis, serum monoclonal component (sMC) value, and altered free light chain ratio (FLCr), were clinically useful to identify SMM patients at higher risk of progression. Time to myeloma progression in our ultra-high risk SMM according to IMWG diagnostic update criteria was very short (12.4 months). Our analysis identified as independent reliable predictors of progression altered FLCr as well as increasing plasma cell infiltration which are part of most commonly applied risk models. Waiting for new scoring systems, bone marrow evaluation and complete laboratory screening are still milestones for SMM management.
KW - bone marrow plasma cells
KW - free light chains
KW - scoring systems
KW - Smoldering myeloma
UR - http://www.scopus.com/inward/record.url?scp=85067614234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067614234&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1620948
DO - 10.1080/10428194.2019.1620948
M3 - Article
C2 - 31169049
AN - SCOPUS:85067614234
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
ER -